Krsnaa Diagnostics Limited (KRSNAA) AI Stock Analysis

• Market Cap: ₹24.96B
• Dividend Yield: 0.34%
• Average Volume (3M): 12.28K
• Price to Earnings (P/E): 31.0
• Beta (1Y): 1.04
• Revenue Growth: 11.51%
• EPS Growth: 21.56%
• Country: IN
• Employees: 3,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 7.60
• Shares Outstanding: 32,438,670
• 10 Day Avg. Volume: 19,408
• 30 Day Avg. Volume: 12,281
• PEG Ratio: 0.98
• Price to Book (P/B): 2.95
• Price to Sales (P/S): 3.63
• P/FCF Ratio: -66.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: ₹828.00 ▲(1.45% Upside)

Krsnaa Diagnostics Limited shows strong financial performance with solid revenue growth and a robust balance sheet. However, technical analysis indicates potential bearish momentum, and the valuation suggests moderate pricing with a low dividend yield. The lack of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market reach and effective service offerings, supporting long-term business sustainability.

Balance Sheet Health

A robust balance sheet with low leverage enhances financial stability and provides flexibility for future investments and growth.

Profit Margins

High profit margins reflect efficient cost management and strong pricing power, contributing to sustainable profitability.

Negative Factors

Free Cash Flow Challenges

Negative free cash flow indicates potential liquidity issues, limiting the company's ability to reinvest in growth and manage debt.

Profitability Metrics

Moderate profitability metrics suggest room for improvement in operational efficiency, impacting long-term competitive positioning.

Capital Expenditure Management

Challenges in capital expenditure management can strain financial resources, affecting the company's ability to fund future growth initiatives.

Krsnaa Diagnostics Limited Business Overview & Revenue Model

Company Description

Krsnaa Diagnostics Limited (KRSNAA) is a leading healthcare service provider in India, specializing in diagnostic services. The company operates in the diagnostic sector, offering a wide range of services including pathology, radiology, and advanced imaging solutions. KRSNAA is known for its commitment to quality healthcare and accessibility, leveraging technology to provide efficient and accurate diagnostic results to patients across various demographics.

How the Company Makes Money

Krsnaa Diagnostics generates revenue primarily through its diagnostic services, including laboratory tests and imaging services. The company operates both a network of diagnostic centers and mobile diagnostic units, allowing it to reach a broad customer base. Key revenue streams include direct payments from patients for diagnostic tests, as well as contracts with hospitals and healthcare providers that refer patients for diagnostic services. Additionally, KRSNAA has established partnerships with government health initiatives and insurance companies, further enhancing its revenue opportunities by providing services through public health schemes and insurance reimbursements.

Krsnaa Diagnostics Limited Financial Statement Overview

Summary

Krsnaa Diagnostics Limited demonstrates strong financial performance with robust revenue growth and profitability. The balance sheet is solid with a strong equity position and low leverage, enhancing financial stability. However, challenges in free cash flow generation present a potential risk, despite stable operating cash flows.

Income Statement

Krsnaa Diagnostics Limited shows strong revenue growth with a notable increase of 15.74% from 2024 to 2025. The company maintains a substantial gross profit margin of 76.38% for 2025, reflecting efficient cost management. However, while the net profit margin improved to 10.82%, there is room for enhancement in profitability metrics such as EBIT and EBITDA margins, which stand at 14.19% and 26.51% respectively. Overall, the income statement indicates a solid performance with positive growth trends.

Balance Sheet

The balance sheet of Krsnaa Diagnostics Limited is quite robust, with a healthy equity ratio of 68.87%, indicating a strong equity position relative to total assets. The debt-to-equity ratio at 0.23 suggests low financial leverage, which is a positive sign for financial stability. Additionally, the return on equity (ROE) is 8.79%, showing decent returns for shareholders. The balance sheet reflects sound financial management with a strong equity base and controlled leverage.

Cash Flow

The cash flow statement reveals challenges in free cash flow generation, with a negative free cash flow of -393 million in 2025, albeit an improvement from the previous year. The operating cash flow to net income ratio of 1.13 is solid, indicating good cash conversion efficiency. However, the company has faced difficulties in managing capital expenditures, which impacts free cash flow. Overall, while operating cash flows are stable, the negative free cash flow presents a potential risk area to address.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.40B	7.17B	6.20B	4.87B	4.55B	3.96B
Gross Profit	4.63B	5.48B	2.05B	4.13B	3.95B	3.13B
EBITDA	2.17B	2.16B	1.61B	1.42B	1.46B	3.59B
Net Income	802.09M	776.08M	568.37M	621.11M	683.88M	1.85B
Balance Sheet
Total Assets	0.00	12.82B	11.72B	9.10B	8.76B	6.05B
Cash, Cash Equivalents and Short-Term Investments	684.36M	684.36M	535.45M	1.09B	2.42B	1.53B
Total Debt	0.00	2.04B	1.60B	324.81M	409.92M	2.32B
Total Liabilities	-8.83B	3.99B	3.62B	1.71B	2.07B	3.73B
Stockholders Equity	8.83B	8.83B	8.10B	7.39B	6.84B	2.32B
Cash Flow
Free Cash Flow	0.00	-393.00M	-1.70B	-650.59M	-37.95M	357.18M
Operating Cash Flow	0.00	873.27M	243.45M	763.01M	1.28B	1.03B
Investing Cash Flow	0.00	-996.09M	-1.29B	-1.09B	-2.41B	-611.39M
Financing Cash Flow	0.00	137.53M	841.87M	-331.45M	1.76B	308.40M

Krsnaa Diagnostics Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 816.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KRSNAA, the sentiment is Positive. The current price of 816.2 is above the 20-day moving average (MA) of 796.72, above the 50-day MA of 806.04, and above the 200-day MA of 769.09, indicating a bullish trend. The MACD of 3.79 indicates Negative momentum. The RSI at 53.62 is Neutral, neither overbought nor oversold. The STOCH value of 56.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KRSNAA.

Krsnaa Diagnostics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	68 Neutral	₹105.28B	70.08	―	0.20%	16.71%	13.92%
HCG	67 Neutral	₹107.77B	287.35	―	―	17.58%	-38.20%
LALPATHLAB	66 Neutral	₹264.07B	49.19	―	0.80%	10.80%	32.79%
MEDICAMEQ	65 Neutral	₹5.59B	50.25	―	0.24%	-9.16%	49.09%
KRSNAA	62 Neutral	₹24.96B	30.99	―	0.34%	11.51%	21.56%
METROPOLIS	61 Neutral	₹105.27B	68.82	―	0.21%	15.41%	5.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Krsnaa Diagnostics Limited Corporate Events

Krsnaa Diagnostics Releases Unaudited Financial Results for September 2025

Krsnaa Diagnostics Limited announced the publication of its unaudited financial results for the quarter and half-year ending September 30, 2025, in prominent newspapers. This disclosure is part of the company’s compliance with SEBI regulations and reflects its commitment to transparency with stakeholders.

Krsnaa Diagnostics Achieves Record Profit, Eyes Future Growth with Rajasthan Expansion

Krsnaa Diagnostics Limited reported its highest-ever quarterly profit, with a 12% year-on-year revenue growth in H1 FY26, driven by expanding patient volumes and confidence in its diagnostic network. The company’s EBITDA increased by 18% year-on-year, reflecting strong operating leverage and disciplined execution. The Rajasthan rollout is expected to unlock future growth potential, further strengthening Krsnaa’s market position. The company’s focus on profitable and sustainable growth is underscored by a 19% rise in net profit, and its strategic partnerships with government entities ensure quality receivables and credibility.

Krsnaa Diagnostics Schedules Investor Meeting to Enhance Stakeholder Engagement

Krsnaa Diagnostics Limited has announced a scheduled meeting with investors and analysts on October 7, 2025, in Pune. The meeting will involve one-on-one interactions with high-net-worth individuals, focusing on publicly available information, ensuring no unpublished price-sensitive information is disclosed. This engagement reflects the company’s commitment to transparency and maintaining strong relationships with its stakeholders.

Krsnaa Diagnostics Releases Q1 2025 Financial Results

Krsnaa Diagnostics Limited announced the publication of its unaudited financial results for the quarter ending June 30, 2025, in prominent newspapers such as Financial Express and Loksatta. This disclosure is part of the company’s compliance with SEBI regulations, reflecting its commitment to transparency and providing stakeholders with timely financial information.

Krsnaa Diagnostics Releases Q1 FY2026 Financial Results

Krsnaa Diagnostics Limited has released an investor presentation detailing its unaudited financial results for the quarter ending June 30, 2025. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic positioning in the diagnostic services industry.